10 drug(s) with this reaction
17,679 total reports
Hospitalisation has been reported as an adverse reaction across 10 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 17,679 adverse event reports mention hospitalisation in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with hospitalisation, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have hospitalisation listed in their FDA adverse event reports, sorted by report count:
In addition to hospitalisation, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
10 drug(s) manufactured by Amgen Inc have hospitalisation listed in their FDA adverse event reports: CINACALCET HYDROCHLORIDE, DARBEPOETIN ALFA, DENOSUMAB, PEGFILGRASTIM, ROMOSOZUMAB-AQQG, and others.
There are a combined 17,679 reports of hospitalisation across 10 Amgen Inc drug(s) in the FDA adverse event database.